Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cureus ; 15(8): e44176, 2023 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-37753022

RESUMO

The aim of this study is to review the potential of strontium-doped nanohydroxyapatite (SrnHAP) as a biomaterial for remineralizing early carious lesions. Publications from 2012 to 2022 were included based on the patient/population, intervention, comparison, and outcomes (PICO) framework, focusing on demineralized enamel treated with strontium-doped nanohydroxyapatite compared to other remineralizing agents, with the primary outcome being remineralization capacity. Electronic databases, namely, PubMed, Cochrane Library, and Google Scholar, were explored from March 31, 2023, to April 10, 2023. Only English language studies were included, while certain research types and studies on bovine teeth were excluded. Bias was assessed using the Cochrane methodology. Five studies were synthesized, all using extracted human maxillary premolars. Four studies focused on remineralizing enamel, while one study focused on remineralizing dentin. Among these studies, comparisons were made between different strontium concentrations and various remineralizing agents such as nanohydroxyapatite (nHAP), Acclaim, casein phosphopeptide-amorphous calcium phosphate (CPP-ACP), and NovaMin. X-ray diffraction analysis was used to examine hydroxyapatite formation, while scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were used for characterization. Additionally, one study evaluated the mechanical properties of partially demineralized dentin specimens. This study was registered in the PROSPERO under the ID CRD42023397413 and completed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

2.
J Pharm Bioallied Sci ; 14(Suppl 1): S962-S964, 2022 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-36110645

RESUMO

Objectives: The objectives of this study is to evaluate apical sealing ability of GuttaFlow Bioseal, Super-Bond RC Sealer, and Adseal root canal sealer. Material and Methods: 36 extracted human single rooted permanent teeth, divided into three groups (n = 12) and obturated by lateral condensation technique. Obturation and root canal sealing was done by either Group I: using GuttaFlow Bioseal, Group II: using Super-Bond RC Sealer and Group III: using Adseal sealer, system. Microleakage was assessed by means of dye penetration method. Results: The dye penetration in Group II was more than in Groups I and III in both vertical and horizontal directions, suggesting that GuttaFlow Bioseal and Adseal sealer are effective in reducing the apical leakage compared to Super-Bond RC Sealer. Conclusion: Bioceramic GuttaFlow Bioseal root canal sealers seal are better root canal sealer but they cannot totally eliminate apical leakage.

3.
BMC Res Notes ; 10(1): 465, 2017 Sep 07.
Artigo em Inglês | MEDLINE | ID: mdl-28882195

RESUMO

BACKGROUND AND AIMS: The relationship between vitamin D deficiency and type I DM is an ongoing area of interest. The study aims to identify the prevalence of vitamin D deficiency in children and adolescents with T1DM and to assess the impact of treatment of vitamin D deficiency on their glycaemic control. METHODS: Retrospective data was collected from 271 children and adolescents with T1DM. The vitamin D deficient (25(OH)D <30 nmol/L) and insufficient (25(OH)D 30-50 nmol/L) patients were treated with 6000 units of cholecalciferol and 400 units of cholecalciferol, once daily for 3 months respectively. HbA1c and 25(OH)D concentrations were measured before and at the end of the vitamin D treatment. RESULTS: 14.8% from the whole cohort (n = 271) were vitamin D deficient and 31% were insufficient. Among the children included in the final analysis (n = 73), the mean age and plasma 25(OH)D concentration (±SD) were 7.7 years (±4.4) and 32.2 nmol/l (±8.2) respectively. The mean 25(OH)D concentration post-treatment was 65.3 nmol/l (±9.3). The mean HbA1c (±SD) before and after cholecalciferol was 73.5 mmol/mol (±14.9) and 65 mmol/mol (±11.2) respectively (p < 0.001). Children with higher pre-treatment HbA1c had greater reduction in HbA1c (p < 0.001) and those with lower 25(OH)D concentration showed higher reduction in HbA1c (p = 0.004) after treatment. CONCLUSIONS: Low 25(OH)D concentrations are fairly prevalent in children and adolescents with T1DM, treatment of which, can potentially improve the glycaemic control.


Assuntos
Colecalciferol/farmacologia , Diabetes Mellitus Tipo 1/sangue , Deficiência de Vitamina D/sangue , Deficiência de Vitamina D/tratamento farmacológico , Criança , Pré-Escolar , Colecalciferol/administração & dosagem , Comorbidade , Diabetes Mellitus Tipo 1/tratamento farmacológico , Diabetes Mellitus Tipo 1/epidemiologia , Feminino , Hemoglobinas Glicadas , Humanos , Masculino , Prevalência , Estudos Retrospectivos , Resultado do Tratamento , Deficiência de Vitamina D/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...